This concept is partially confirmed by another publication showing that TSHR mRNA expression level could serve as a biomarker to predict the response of adjuvant intravenous platinum-taxane chemotherapy in patients with ovarian cancer, wherein those with increased TSHR mRNA level are associated with poorer clinical outcomes [60]. Here, TSHR is linked to ovarian cancer.